^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

89P - Durvalumab could be effective in combination with anti-HER2 agents in HER2-low breast cancer

Published date:
12/01/2022
Excerpt:
Our findings revealed synergistic effects in HER2-low BC patient-derived organoids when treated with T-Dxd and or trastuzumab in combination with durvalumab. We also observed antibody-dependent cellular cytotoxicity (ADCC) response with trastuzumab in combination with durvalumab....Altogether, despite preliminary, these findings support the rationale for combining anti-HER2 therapies with immunotherapy in HER2-low BC patients.